Aicuris
aicuris.com
Actively hiring
Infectious Disease Therapeutics
As featured in
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
News
Aicuris Receives FDA Priority Review for Pritelivir NDA and Presents New Phase 3 Data at ESCMID 2026
The U.S. Food and Drug Administration has granted Priority Review for Aicuris' New Drug Application for pritelivir, a novel helicase primase inhibitor developed to treat refractory herpes simplex virus infections, with or without resistance (RR), in immun
Read more
Report
Asahi Kasei: €780 Million Acquisition Of Aicuris To Expand Severe Infectious Disease Platform
Asahi Kasei announced it has entered into a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a German-based biopharmaceutical company, for approximately €780 million, or about $919 million at an exchange rate of $1.178
Read more
Report
Aicuris Presents Pharmacokinetic Data From The First-In-Human Clinical Trial Of AIC468, A Novel Antisense Oligonucleotide Targeting BK Virus, At World Transplant Congress
Read more
Report
AiCuris Initiates First-in-Human Phase 1 Trial With Antiviral Agent AIC468 to Address BK Virus Infections in Kidney Transplant Recipients
Read more
Report
AiCuris and Hybridize Therapeutics Enter Worldwide License Agreement of up to €100M for a Direct-Acting RNA-Based Therapy Against BK Virus
The licensed program is based on a novel RNA-based therapeutic approach developed by Hybridize.Under the terms of the agreement, AiCuris will gain exclusive rights to develop and commercialize Hybridize
Read more
Report
AiCuris was Granted Breakthrough Therapy Designation by U.S. FDA for Pritelivir for the Treatment of HSV Infections in Immunocompromised Patients
WUPPERTAL, GERMANY / ACCESSWIRE / June 5, 2020 / AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, today announced that the Company has been granted Breakthrough Therapy designation
Read more
Report
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targetin
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus WHITEHOUSE STATION, N.J. & WUPPERTAL, GERMANY--(BUSINESS WIRE)-- Merck (NYS: MRK) , known as MSD outside the
Read more
Report
AiCuris and Merck Announce Publication in New England Journal of Medicine of Phase 2 Clinical Trial Results of Investigational Antiviral Agent Letermovir in Bone Marrow ...
Read more
Report
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targetin
AiCuris and Merck Enter Exclusive Worldwide License Agreement for Investigational Portfolio Targeting Human Cytomegalovirus WHITEHOUSE STATION, N.J. & WUPPERTAL, GERMANY--(BUSINESS WIRE)-- Merck (NYS...
Read more
Report
Show more news
Tech stack
Technologies named in job postings at Aicuris over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~1 days
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Science & Research
100% ▼
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
1
Countries
2
Busiest office
Wuppertal
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Wuppertal
Germany
Regional office
Aicuris Anti-infective Cures AG
1 open roles 1 posted in 90 days 100% engineering
hires for Science & Research
Friedrich-Ebert-Str. 475 / Building 302, 42117 Wuppertal Germany
Waltham
United States
Regional office
Aicuris US Inc.
201 Jones Road, Waltham, MA 02451, USA